Although the survival rate for early detected cancers is high, once a cancer metastasizes to bone, it is incurable. Interestingly, patients without visible metastases display abnormal bone formation and resorption, suggesting a link between primary cancers and the bone microenvironment prior to metastasis, and this link likely facilitates preparation of the pre-metastatic niche. We hypothesized that communication with the primary tumor would result in bone remodeling alterations, and that platelets could facilitate this communication. By using three tumor models, we demonstrate that primary tumor growth stimulates bone formation measured by microcomputed tomography. Further, platelet depletion prevented tumor-induced bone formation, highlighting the importance of platelets in the communication between tumors and the bone microenvironment. Finally, we determine that platelets sequester a variety of tumor-derived proteins, TGF-b1 and MMP-1 in particular, which regulate bone formation. Thus, our data reveal that platelets function as mediators of tumor-bone communication prior to metastasis.
INTRODUCTION
Approximately 80% of advanced prostate cancers and 25-49% of advanced melanomas metastasize to the skeleton causing pain in the hips, spine, ribs or other bones.
1,2 Once a cancer produces bone metastases, it becomes incurable. 3 Both prostate cancer and melanoma have survival rates of B100% if localized when diagnosed. However, the 5-year survival rate drops to 30% for prostate cancer and 16% for melanomas once distant metastases have developed. 4 Interestingly, a majority of patients with prostate cancer are found to have a significant number of tumors within the bone at autopsy, although they are largely asymptomatic. In patients, primary prostate cancer induces the abnormal formation and turnover of bone prior to metastasis. 5 The growth of primary tumors is aided by the presence of a variety of factors sequestered in and released from the bone matrix during remodeling and those produced by activated osteoclasts and osteoblasts, such as parathyroid hormone-related protein, RANKL, TGF-b1, basic fibroblast growth factor, insulin-like growth factor, Ca 2 þ and osteonectin/ SPARC. 6 Thus, the cancer cells and bone microenvironment interact in a positive-feedback cycle to enhance tumor aggressiveness.
Vascularization of the primary tumor and metastasis of cancer cells through the bloodstream allow for interaction between the cancer cells and platelets. Further, metastatic tumor cells may travel through the bloodstream as small thrombi with platelets 7 for protection against shear stress. In addition, platelets are activated within tumors, where they may release or acquire proteins. The releasate of platelets contains anti-and pro-angiogenic factors, such as VEGF, TGF-b1 and thrombospondin-1, which can control tumor growth. Increased levels of VEGF in the serum and platelets directly correlate with increased tumor metastasis. 8 We have recently shown that platelets mediate tumor communication with the bone marrow resulting in bone marrow-derived cell mobilization. 9 Proteins released from activated platelets can also function directly on bone, thereby stimulating proliferation of osteoblasts, inducing regeneration of bone 10, 11 and promoting the differentiation of osteoclast-like cells. 12 Further, platelet-rich plasma, which contains activated and resting platelets, stimulates mesenchymal stem cell osteogenesis. 13 Thus, platelets may have an important role in the growth of primary tumors, and facilitate the tumor spread by preparing the future metastatic site.
Despite the progress made over the last decade in the treatment of cancer, the mechanisms governing its metastatic development in bone remain enigmatic. Recent clinical evidence indicates that the primary tumors communicate with bone prior to metastasis. However, the participating factors in the crosstalk between tumor and the bone microenvironment that mediate tumor homing and contribute to tumor growth within the skeleton remain to be determined. In this study, we elucidate the effects of primary tumor growth on bone metabolism using murine prostate cancer (RM1) or murine melanoma (B16-F10) cells implanted in immunocompetent mice, or human prostate cancer (LNCaP-C4-2) cells implanted in immunocompromised mice. These three different tumor models were used to assess the changes in bone structure induced by distal tumor. By using platelet depletion, we demonstrate that platelets are required for tumor-induced bone formation, and using our xenograft model we identify tumor-derived proteins sequestered in platelets that may be responsible for tumor-induced bone formation.
RESULTS AND DISCUSSION
Primary tumor growth stimulates bone formation We have previously demonstrated that direct injection of tumors into the bone environment results in alterations in bone turnover. turnover prior to metastasis. However, established cancer metastases can be either osteoblastic or osteolytic. In our previous studies, intratibial injection of murine prostate cancer RM1 cells resulted in osteolysis, 14, 16 whereas human prostate cancer LNCaP-C4-2 injection resulted in bone formation. 15 In the present study, we determined the effects of distal, primary tumor growth on bone turnover. By using three models, such as murine RM1 prostate cancer and murine B16-F10 melanoma in immunocompetent mice and human LNCaP-C4-2 prostate cancer in immunodeficient mice, we measured bone structural indices in mice 1 day before and 9, 12 or 19 days after tumor implantation for B16-F10, RM1 and LNCaP-C4-2, respectively ( Figure 1a and Supplementary Table 1 ). The bone structural indices were not significantly different between the groups at the initial time point. As measured by microcomputed tomography (microCT), ratio of bone volume to total volume (BV/TV) at the final time point was increased in tumor-bearing mice for all models, 1.28-fold for B16-F10-, 1.63-fold for RM1-and 1.79-fold for LNCaP-C4-2-injected mice compared with control ( Figure 1b) . Bone surface area was increased in B16-F10-, RM1-and LNCaP-C4-2-implanted mice by 1.62-, 1.21-and 1.75-fold, respectively, compared with control mice (Figure 1c ). Trabecular thickness was increased in RM1-and LNCaP-C4-2-injected mice compared with controls by 1.37-and 1.23-fold, respectively (Figure 1d ). Interestingly, melanoma-injected mice displayed increases in trabecular number (Tb.N; 1.29-fold), whereas the prostate cancer-injected mice demonstrated no significant change in Tb.N compared with control ( Figure 1e ). To confirm that the increased bone in mice bearing tumors was due to osteoblast activation, plasma concentrations of osteocalcin and bone alkaline phosphatase were measured (Figure 2) . Osteocalcin was increased in B16-F10-, RM1-and LNCaP-C4-2-implanted mice by 1.44-, 1.25-and 1.48-fold, respectively, compared with control mice (Figure 2a ). Correspondingly, bone alkaline phosphatase was increased in B16-F10-, RM1-and LNCaP-C4-2-implanted mice by 1.53-, 1.49-and 1.20-fold, respectively, compared with control mice (Figure 2b ). During the same period, plasma calcium concentrations were altered slightly with levels being increased in immunocompetent mice and decreased in the immunocompromised mice (Supplementary Figure 1) . Together, our data demonstrates that distal tumor growth stimulates bone formation in three different in vivo tumor models. This data has been confirmed clinically by studies demonstrating that primary tumors stimulate abnormal bone formation in patients. 5 Although it is known that prostate cancer cells preferentially metastasize to trabecular bone and cause osteoblastic lesions, 18, 19 this is the first report showing that other tumors, such as melanomas, are capable of changing the bone structure.
Platelet depletion inhibits tumor-induced bone formation We next addressed the mechanism of distal tumor communication with the bone tissue by testing our hypothesis that this interaction is mediated by circulating platelets. Indeed, platelet contents are known to stimulate bone formation during fracture repair, 10, 11 and we have recently shown the role of platelets in communications between ischemic tissues and bone marrow. 9 Using our B16-F10 tumor model, we depleted platelet levels using a GPIba antibody to diminish platelet levels by 90% compared with control immunoglobulin G, as shown previously by Feng et al. 20 and others. 21 We chose to focus on the B16-F10 tumor model because Figure 1 . Distal tumor growth stimulates bone formation. Tumor cells were implanted subcutaneously into male mice: B16-F10 murine melanoma (2 Â 10 6 cells in C57BL/6 mice, 9 weeks of age), RM1 murine prostate cancer (4 Â 10 5 cells in C57BL/6 mice, 9 weeks of age) and LNCaP-C4-2 human prostate cancer (4 Â 10 5 cells encapsulated in matrigel in NOD/SCID mice, 8 weeks of age; black columns). Age-matched control mice were injected with phosphate-buffered saline (for C57BL/6 mice) or matrigel (NOD/SCID mice; white columns). Tibial bones were scanned using microCT prior to (in vivo) and upon experimental termination (ex vivo): 9 days (B16-F10), 12 days (RM1) or 19 days (LNCaP-C4-2) after tumor implantation. (a) Representative microCT scans of the analyzed metaphyseal area (first 20 slices cropped) from control and mice bearing B16-F10, RM1 or LNCaP-C4-2 at the final time point are shown. (b-e) Bone morphometric changes were measured using a GE Healthcare eXplore Locus MicroCT scanner (Piscataway, NJ, USA) with 360 X-ray projections collected at 11 increments and projected images reconstructed into three-dimensional volumes at 20 mm resolution, as previously described 14, 16, 41 its changes in Tb.N and trabecular spacing, with no significant change in trabecular thickness, indicate de novo bone formation (Figure 1 ), in which bone forms in a process similar to fracture repair. We found that BV/TV was increased 1.51-fold in mice bearing tumors compared with control (Figures 3a and b) . Platelet depletion prevented tumor-induced bone formation, as levels of BV/TV, Tb.N and bone surface area in platelet-depleted animals were similar to control animals without tumor (Figure 3 and  Supplementary Table 2 ). However, platelet infusion was unable to significantly increase bone formation over that already induced by the tumor (Supplementary Table 2 ). In addition, platelet depletion in control mice, not bearing tumors, had no effect on bone structure (data not shown). Our data indicate that platelets are necessary for tumor-induced bone formation. Diminishing platelet levels correlated with a decrease in the development of metastases in mice. 22 In addition, inhibiting the ability of platelets to bind tumor cells results in a decreased number of cells colonizing metastatic tissues. 23 Further, incubation of bone marrow-derived cells with platelet releasates results in increased cell migration and proliferation, 24 which may cause osteogenesis during bone regeneration. During fracture healing, increasing levels of platelets in platelet-rich plasma gel results in improved bone formation, non-union closure and mineralization of the callus. 10 Further, platelet-rich plasma stimulates both mesenchymal stem cell and osteoblast proliferation and differentiation. 11, 25 Correspondingly, when we treated murine osteoblast MC3T3-E1 cells with platelet releasates from mice bearing B16-F10 tumors, osteoblast mineralization was significantly increased (Figure 3f) . Thus, proteins released upon platelet activation may stimulate osteoblast differentiation resulting in increased bone formation.
Platelets sequester proteins related to bone metabolism Our findings demonstrate that platelets are required for bone formation in response to tumor growth. Importantly, platelets are able to accumulate proteins within their a-granules regardless of a concentration gradient, and segregate these proteins resulting in differential release to stimulate specific pathways in recipient cells. 26, 27 We used a tumor xenograft model to determine what tumor-produced factors sequestered by platelets were capable of modulating bone formation. Using our LNCaP-C4-2 model, platelets were isolated from whole blood, lysed and assayed using an enzyme-linked immunosorbent assay-based, humanspecific protein array to determine the levels of tumor-derived proteins within the platelets. Several factors associated with bone metabolism were found to be tumor derived and present within platelet lysates. No human-derived proteins were measured in control animals, demonstrating the assay specificity (Figure 4a ). We have also measured VEGF, G-CSF and MMP-9 in the range of 130-1050 pg/ml in platelet lysates from tumor-bearing mice. 9 Remarkably, TGF-b1 was present at the highest concentration in the platelet compartment (Figure 4a ). TGF-b1 promotes tumor progression and skeletal metastasis of several cancers. 28, 29 Our analysis showed that TGF-b1 was produced by the tumor and was present at 126 425 pg/ml in the platelet lysates of tumorbearing mice (Figure 4a ). In agreement with previous studies, it appears that platelets serve as a key reservoir of TGF-b1 in the circulation. 30 ,31 TGF-b1 stimulates osteoblast maturation, proliferation and subsequent bone formation, suggesting an important role in tumor-induced bone formation. VEGF also stimulates osteoblast maturation and initial matrix calcification. 32 TGF-b1 treatment promotes bone formation in vivo.
33 TGF-b1 stimulation induces VEGF production in osteoblast-like cells, which may further stimulate bone formation. 32, 34, 35 MMP-1, MMP-3, MMP-13 and tissue inhibitor of metalloproteinase (TIMP)-2 concentrations in platelet lysates ranged from B13 750 to 210 pg/ml (Figure 4a) . MMPs produced by the tumor may degrade the bone matrix leading to the release of IGF, TGF-b1 and BMPs, resulting in osteoblast mobilization and mineralization. In addition, the exposed bone matrix recruits osteoblasts to repair the bone resulting in increased bone formation. 36 MMP-1, MMP-13, TIMP-1 and TIMP-2 are expressed by osteoblasts at the base of the growth plate. 37 TIMPs are involved in bone formation and may neutralize excessive bone degradation by the MMPs. RANK and RANKL are believed to target bone tissues and control tumor metastasis, 38, 39 and were present at B5200 and 625 pg/ml, respectively (Figure 4) . RANKL was tumor derived and may stimulate osteoclast differentiation resulting in further release of trapped growth factors from the bone matrix; thus, potentially stimulating osteoblasts and prostate cancer cells. Tumors also produce soluble RANK, which would compete with osteoclasts for RANKL and may diminish the effects of RANKL production. To confirm that platelet-derived TGF-b1 and MMP-1 are increased in mice bearing tumors, we measured the concentrations of the two proteins in platelet releasates. TGF-b1 levels were significantly higher in mice bearing the prostate cancer, whereas it was slightly decreased in mice bearing melanoma ( Supplementary Figures 2A and B) . MMP-1 levels, conversely, were highly elevated in mice with B16-F10 tumors and not significantly changed in RM1-implanted mice (Supplementary Figure 2C) . In addition to these increases in bone remodeling factors in platelets, in response to some tumor types, but not others, the MMPs and TGF-b1 were also increased in the plasma of tumor-bearing mice (Kerr et al. 40 and data not shown) and thus, there remains a possibility that plasma-derived proteins are also contributing to altered bone remodeling. These data indicate that the proteins sequestered within platelets and circulating in plasma in response to tumors may be specific to individual tumor types. Further, the xenograft model demonstrates that tumorderived proteins can be internalized by and sequestered within platelets. Thus, it appears that communication between tumor and bone is mediated by platelets as carriers of factors stored in their granules.
To determine whether these tumor-derived human proteins could affect osteoblast differentiation and function, we treated murine MC3T3-E1 osteoblast cells with ascorbic acid to induce differentiation in the presence of platelet releasates from mice bearing LNCaP-C4-2 tumors. These cells were further treated with human-specific neutralizing antibodies for MMP-1 and TGF-b1, in addition to the broad MMP inhibitor marimastat, to inhibit the tumor-derived proteins found at the highest concentration in platelets (Figure 4a ). The treatment of osteoblasts with platelet releasates from tumor-bearing mice significantly increased osteoblast differentiation after 14 days of culture as shown by alizarin red staining (Figure 4b ). Broad MMP inhibition using marimastat significantly inhibited osteoblast function in cultures treated with tumor-derived proteins (Figure 4b ). Neutralization of ) tumor cells were implanted subcutaneously in 9 week old C57BL/6 mice (black columns). Control mice were injected with phosphate-buffered saline (white column). After tumor implantation, mice were treated with rat anti-mouse GPIba (PLT Depletion) or rat immunoglobulin G (IgG; Tumor Alone and Control; 2 mg/g body weight, each; Emfret Analytics, Eibelstadt, Germany) by tail vein injection. Injections were repeated every 3 days. Tibial bones were scanned using microCT prior to (in vivo) and 9 days after tumor implantation (ex vivo). (a) Representative microCT scans of bones from control, tumor alone and platelet-depleted mice at the final time point are shown (first 20 slices cropped). Bone morphometric changes were measured using a GE Healthcare eXplore Locus MicroCT scanner with 360 X-ray projections collected at 1 o increments and projected images reconstructed into three-dimensional volumes at 20 mm resolution for (b) bone volume to total volume ratio (BV/TV), (c) bone surface area (BSA), (d) average trabecular thickness (Avg Tb.Th) and (e) average trabecular number (Avg Tb.N). Values are represented as mean fold change over control±s.e.m. (n ¼ 4). *Po0.05, **Po0.01 and ***Po0.005 vs control or tumor alone samples by paired Student's t-test. (f ) Osteoblast MC3T3-E1 cells on collagen I-coated plates were differentiated for 14 days using 50 mM ascorbic acid (Wako, Richmond, VA, USA) in the presence of control or 1% activated platelet releasate collected from mice bearing B16-F10 tumors (B16-F10 PLT). To induce mineralization, 10 mM bglycerophosphate (Sigma, St Louis, MO, USA) was added after day 6. Alizarin red staining for mineralization was performed as previously described. 42 Densitometry of staining was performed using NIH ImageJ (Bethesda, MD, USA) and represented as mean arbitrary units (A.U.) ± s.e.m. (n ¼ 2-3). *Po0.05 vs control by unpaired Student's t-test.
TGF-b1 decreased alizarin red staining in the cultures treated with platelet releasates, with no effect in control cultures (Figure 4b) . Neutralization of MMP-1 slightly decreased osteoblast function in cultures treated with platelet releasates (Figure 4b ). The inhibitors had no effect on control cultures, indicating that only the human proteins from the tumor present in platelet releasates were being affected. Interestingly, specifically blocking only the tumor-derived TGF-b1 and MMPs, with the growth factors in serum and those produced by the MC3T3-E1 cells still available, resulted in significant decreases in osteoblast function. These data demonstrate that inhibition of tumor-derived proteins can have profound effects on osteoblast differentiation and function, underscoring the potential of these tumor-derived proteins to be targeted in treatments to prevent metastasis.
In conclusion, we demonstrate that distal tumors are able to change bone structure by means of circulating platelets. Primary tumor growth stimulated increased BV/TV in three distinct tumor models. Platelet depletion inhibited bone formation in response to tumor growth. BV/TV and Tb.N are increased in mice bearing tumors; however depletion of platelets results in BV/TV and Tb.N levels similar to mice without tumors. Using a xenograft model and species-specific protein arrays, we demonstrate that platelets uptake high concentrations of tumor-secreted proteins associated with the control of bone metabolism. Thus, platelets regulate the bone formation induced by tumors through the uptake of tumor-derived proteins, and likely through the secretion of their a granule contents possibly resulting in osteoblast differentiation and maturation. This pre-metastatic communication identifies a possible therapeutic target for controlling or detecting early metastasis, which, in turn, will improve the survival rates of cancer patients. 5 human LNCaP-C4-2 cells. After 28 days of tumor growth, platelets were isolated from whole blood of control (white columns) and tumor-bearing (black columns) mice by centrifugation, and lysed in RIPA buffer (Sigma) containing 1 mM protease inhibitors. The resulting lysates were assayed with a customdesigned Quantibody human-specific protein array (RayBiotech, Norcross, VA, USA) to detect tumor-derived proteins according to the manufacturer's protocol. Values were extracted using the Axon Gene Pix Pro 4.1 (Molecular Devices, Sunnyvale, CA, USA) software and analyzed using the RayBiotech Custom Raybio Q-Analyzer software, which uses standardized dilutions of each protein to create standard curves used in determining the concentration in pg/ml of each protein in the samples; represented as mean values ± s.e.m. (n ¼ 4). No tumor-derived proteins were found in the platelets of control mice, demonstrating the specificity of the array. *Po0.05 vs control by unpaired Student's t-test. (b) Osteoblast MC3T3-E1 cells on collagen I-coated plates were differentiated using 50 mM ascorbic acid in the presence of control or 1% activated platelet releasate collected from mice bearing LNCaP-C4-2 tumors (LNCaP-C4-2 PLT). Cultures were grown in the presence of 1 mg/ml anti-human MMP-1 neutralizing antibody (nMMP-1; R&D Systems, Minneapolis, MN, USA), 0.6 mM marimastat (Sigma), 1 mg/ml antihuman TGF-b1 neutralizing antibody (nTGF-b1; R&D Systems) or vehicle control for 14 days. To induce mineralization, 10 mM bglycerophosphate was added after day 6. Alizarin red staining for mineralization was performed as previously described. 42 Densitometry of staining was performed using NIH ImageJ and represented as mean % of control ± s.e.m. (n ¼ 2-3). *Po0.05, **Po0.01 and ***Po0.005 vs control or vehicle by unpaired Student's t-test.
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